T1	Participants 929 1031	652 patients with symptomatic VMA/VMT, including when associated with a macular hole 400 Î¼m or smaller
T2	Participants 1690 1723	464 patients received ocriplasmin
T3	Participants 1728 1748	188 received placebo
